Condition: Atrial Fibrillation · HFpEF - Heart Failure With Preserved Ejection Fraction · Sponsor: The First Affiliated Hospital with Nanjing Medical University
To investigate whether RFCA is superior to AADs in AF patients with HFpEF on the basis of optimized anti-heart-failure drug therapy regarding their longterm clinical outcomes.
This description comes directly from the study's public registry record.
Hailei Liu, PhD · +86-18094226858 · liuhailei@njmu.edu.cn
Nan Wu, MD · +86-18351977986 · wunannjmu@163.com
Always discuss trial participation with your own doctor first.
| the First Affiliated Hospital of Nanjing Medical University | Nanjing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06125925